ChiMed announces data from NSCLC clinical studies to be presented at WCLC
Hutchison China MediTech announced that results from two non-small cell lung cancer clinical studies will be presented at WCLC in Vienna, Austria, December 4-7. Results from the positive Phase II third-line NSCLC clinical trial of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors, will be detailed in an oral presentation. Results from the ongoing Phase Ib first-line NSCLC clinical trial of epitinib, a highly selective inhibitor of the epidermal growth factor receptor designed to optimize brain penetration, will also be presented. In September 2015, Chi-Med announced that the fruquintinib Phase II NSCLC clinical trial had successfully achieved its primary endpoint. The oral and poster presentations will include more mature data than those included in the following fruquintinib and epitinib study abstracts.